Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

Cell Death and Differentiation

Volumn 21, Issue 1, 2014, Pages 39-49

  Inoue, H ^a,b,c   Tani, K ^a,c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

apoptosis; DAMPs; ICD; immunotherapeutic anticancer agents; necroptosis; oncolytic virotherapy

Indexed keywords

7A 7; 7A7; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CARDIAC GLYCOSIDE; CASPASE INHIBITOR; CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; HSV 1716; HYPERICIN; JX 547; M PROTEIN; MITOXANTRONE; ONCOLYTIC VIRUS; OXALIPLATIN; PEXA VEC; PROTEIN P53; RECOMBINANT BETA INTERFERON; SHIKONIN; T VEC; TALIMOGENE LAHERPAREPVEC; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; VORINOSTAT;

AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRUCTURE; DENDRITIC CELL; DRUG CYTOTOXICITY; ENZYME RELEASE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; NECROPTOSIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; VACCINIA VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CALRETICULIN; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; HMGB1 PROTEIN; HUMANS; NEOPLASMS; ONCOLYTIC VIRUSES;

EID: 84890086459     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.84     Document Type: Review

References (140)

1. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
4. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079.
5. Tanimoto T, Hori A, Kami M. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 1967-1968; 1966; author reply.
6. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
7. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-336.
8. Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 2011; 19: 335-344.
9. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72: 2609-2621.
10. Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P et al. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res 2010; 70: 9837-9845.
11. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
12. Curtin JF, Cotter TG. Apoptosis: Historical perspectives. Essays Biochem 2003; 39: 1-10.
13. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012 19: 107-120.
14. Brenner C, Kroemer G. Apoptosis. Mitochondria-The death signal integrators. Science 2000; 289: 1150-1151.
15. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
16. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14: 715-725.
17. Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P et al. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ 2011; 18: 1316-1325.
18. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
19. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-Apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-590.
20. Merritt RE, Mahtabifard A, Yamada RE, Crystal RG, Korst RJ. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1609-1617.
21. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14: 1848-1850.
22. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72: 3967-3976.
23. Rubner Y, Wunderlich R, Ruhle PF, Kulzer L, Werthmoller N, Frey B et al. How does ionizing irradiation contribute to the induction of anti-Tumor immunity? Front Oncol 2012; 2: 75.
24. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-305.
25. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
26. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2012; 31: 51-72.
27. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875.
28. Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013.
29. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M et al. The co-Translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15: 1499-1509.
30. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
31. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
32. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71: 768-778.
33. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011; 30: 4297-4306.
34. Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 2009; 124: 2450-2459.
35. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 2007; 109: 4839-4845.
36. Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; 187: 4954-4966.
37. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4: 143ra199.
38. Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66: 611-616.
39. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649.
40. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012; 31: 1055-1057.
41. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012; 19: 1880-1891.
42. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
43. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010; 11: 562-594.
44. Zhang L, Wang A. Virus-induced ER stress and the unfolded protein response. Front Plant Sci 2012; 3: 293.
45. Schwarz KB. Oxidative stress during viral infection: A review. Free Radic Biol Med 1996; 21: 641-649.
46. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-Associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61: 215-221.
47. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007; 220: 22-34.
48. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-1556.
49. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-1158.
50. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
51. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
52. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-570.
53. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol 2008; 20: 504-511.
54. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842.
55. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
56. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-11947.
57. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301.
58. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 2012; 106: 57-61.
59. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE. Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 2006; 312: 3526-3538.
60. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-1528.
61. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18: 250-259.
62. Chaiswing L, Oberley TD. Extracellular/microenvironmental redox state. Antioxid Redox Signal 2010; 13: 449-465.
63. Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: Characterization, redox considerations, and novel approaches for reactive oxygen species-Targeted gene therapy. Antioxid Redox Signal 2012.
64. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005; 65: 9991-9998.
65. Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72: 2327-2338.
66. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
67. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-3728.
68. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
69. Ohshima Y, Tsukimoto M, Takenouchi T, Harada H, Suzuki A, Sato M et al. Gamma-irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 2010; 1800: 40-46.
70. Petrovski G, Ayna G, Majai G, Hodrea J, Benko S, Madi A et al. Phagocytosis of cells dying through autophagy induces inflammasome activation and IL-1beta release in human macrophages. Autophagy 2011; 7: 321-330.
71. Chang CW, Li HC, Hsu CF, Chang CY, Lo SY. Increased ATP generation in the host cell is required for efficient vaccinia virus production. J Biomed Sci 2009; 16: 80.
72. Seror C, Melki MT, Subra F, Raza SQ, Bras M, Saidi H et al. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med 2011; 208: 1823-1834.
73. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752.
74. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13: 7271-7279.
75. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717-1721.
76. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: Apoptosis, autophagy and the cross-Talk between them. Cell Death Differ 2009; 16: 966-975.
77. Kroemer G, Levine B. Autophagic cell death: The story of a misnomer. Nat Rev Mol Cell Biol 2008; 9: 1004-1010.
78. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN et al. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell 2007; 128: 931-946.
79. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8: 413-415.
80. Townsend KN, Hughson LR, Schlie K, Poon VI, Westerback A, Lum JJ. Autophagy inhibition in cancer therapy: Metabolic considerations for antitumor immunity. Immunol Rev 2012; 249: 176-194.
81. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-336.
82. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther 2011; 10: 1533-1541.
83. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: A specific form of programmed cell death? Exp Cell Res 2003; 283: 1-16.
84. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
85. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3: Re4.
86. Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
87. Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: To break or to burst, that's the question. Cell Mol Life Sci 2010; 67: 1567-1579.
88. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 2006; 1757: 1371-1387.
89. Golstein P, Kroemer G. Cell death by necrosis: Towards a molecular definition. Trends Biochem Sci 2007; 32: 37-43.
90. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
91. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
92. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-661.
93. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18: 1272-1282.
94. Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006; 11: 473-485.
95. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
96. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-Apoptotic protein Bcl-2 in breast tumours. Cancer Immun 2009; 9: 4.
97. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: Host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109.
98. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003; 35: 685-694.
99. Colunga AG, Laing JM, Aurelian L. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther 2010; 17: 315-327.
100. Wang Q, Imamura R, Motani K, Kushiyama H, Nagata S, Suda T. Pyroptotic cells externalize eat-me and release find-me signals and are efficiently engulfed by macrophages. Int Immunol 2013; 25: 363-372.
101. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18: 1430-1439.
102. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. Viral control of mitochondrial apoptosis. PLoS Pathogen 2008; 4: E1000018.
103. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-335.
104. Meng X, Nakamura T, Okazaki T, Inoue H, Takahashi A, Miyamoto S et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-Type N, P, L genes on human renal cell carcinoma. Mol Ther 2010; 18: 544-551.
105. Hasei J, Sasaki T, Tazawa H, Osaki S, Yamakawa Y, Kunisada T et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther 2013; 12: 314-325.
106. Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J et al. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 2010; 70: 1367-1376.
107. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
108. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: A novel form of immunotherapy. Expert Rev Anticancer Ther 2008; 8: 1581-1588.
109. Kepp O, Senovilla L, Galluzzi L, Panaretakis T, Tesniere A, Schlemmer F et al. Viral subversion of immunogenic cell death. Cell Cycle 2009; 8: 860-869.
110. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3(Part 1): 697-707.
111. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12: 789-802.
112. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-549.
113. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 6018-6026.
114. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013; 20: 7-15.
115. Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-Tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 2011; 18: 164-172.
116. Borde C, Barnay-Verdier S, Gaillard C, Hocini H, Marechal V, Gozlan J. Stepwise release of biologically active HMGB1 during HSV-2 infection. PLoS One 2011; 6: E16145.
117. Moisy D, Avilov SV, Jacob Y, Laoide BM, Ge X, Baudin F et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J Virol 2012; 86: 9122-9133.
118. Zhang HM, Ye X, Su Y, Yuan J, Liu Z, Stein DA et al. Coxsackievirus B3 infection activates the unfolded protein response and induces apoptosis through downregulation of p58IPK and activation of CHOP and SREBP1. J Virol 2010; 84: 8446-8459.
119. Chau DH, Yuan J, Zhang H, Cheung P, Lim T, Liu Z et al. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis 2007; 12: 513-524.
120. Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 2006; 98: 625-636.
121. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-1414.
122. Tazawa H, Yano S, Yoshida R, Yamasaki Y, Sasaki T, Hashimoto Y et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer 2012; 131: 2939-2950.
123. Meng C, Zhou Z, Jiang K, Yu S, Jia L, Wu Y et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol 2012; 157: 1011-1018.
124. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy 2013; 9: 413-414.
125. Hu X, Xuan Y. Bypassing cancer drug resistance by activating multiple death pathways-A proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 2008; 259: 127-137.
126. Huang H, Xiao T, He L, Ji H, Liu XY. Interferon-beta-Armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 737-745.
127. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120: 1151-1164.
128. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
129. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-Tumor mechanisms in mouse models. Mol Ther 2001; 4: 356-364.
130. Chiocca EA. The host response to cancer virotherapy. Curr Opin Mol Ther 2008; 10: 38-45.
131. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: Immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008-1016.
132. Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 2008; 16: 1910-1918.
133. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: Exploring the unknown. Photochem Photobiol Sci 2011; 10: 670-680.
134. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 2012; 1: 786-788.
135. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008; 324: 95-102.
136. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
137. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
138. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
139. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011; 17: 3686-3696.
140. Cripe TP,Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009; 17: 1677-1682. Technology Technology